Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. SBUX
9. AXP
10. ZETA

Go back to Bristol-Myers Squibb (BMY) Reports In-Line Q2 EPS, Updates FY EPS Guidance

Bristol-Myers Squibb Co. (BMY) PT Lowered to $61 at Leerink Partners

July 28, 2017 10:31 AM EDT

Leerink Partners lowered its price target on Bristol-Myers Squibb Co. (NYSE: BMY) to $61.00 (from $66.00) while maintaining a Outperform rating following the company's 2Q. BMY delivered in line earnings of 74c.

Analyst Seamus Fernandez now forecasts a 9% EPS growth in 2018-22E excluding Opdivo +... More